Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling

American Journal of Surgical Pathology

Volumn 39, Issue 10, 2015, Pages 1322-1330

  Yuan, Ji ^a   Wright, George ^b   Rosenwald, Andreas ^c   Steidl, Christian ^d   Gascoyne, Randy D ^d   Connors, Joseph M ^d   Mottok, Anja ^d   Weisenburger, Dennis D ^e   Greiner, Timothy C ^a   Fu, Kai ^a   Smith, Lynette ^f   Rimsza, Lisa M ^g   Jaffe, Elaine S ^h   Campo, Elias ⁱ   Martinez, Antonio ⁱ   Delabie, Jan ^j   Braziel, Rita M ^k   Cook, James R ^l   Ott, German ^m   Vose, Julie M ^f   Staudt, Louis M ^b   Chan, Wing C ^e   more..

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j UNIVERSITY OF OSLO   (Norway)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m ROBERT BOSCH HOSPITAL   (Germany)

more..

Author keywords

CIITA; Gene expression profiling; PDL1 2; Primary mediastinal large B cell lymphoma

Indexed keywords

CD274 PROTEIN, HUMAN; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; CHEMISTRY; CHROMOSOME 9; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; MALE; MEDIASTINUM TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOMARKERS, TUMOR; CHROMOSOMES, HUMAN, PAIR 9; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NUCLEAR PROTEINS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84941793201     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000473     Document Type: Article

References (31)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: Internation Agency for Research on Cancer (IARC); 2008:358-360.
2. Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol. 1996;20:877-888.
3. Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17:123-130.
4. Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87:1258-1264.
5. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-862.
6. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871-3879.
7. Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60:549-552.
8. Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood. 1996;87:1571-1578.
9. Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer. 2001;30: 393-401.
10. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411-1421.
11. Bishop PC, Wilson WH, Pearson D, et al. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol. 1999;17: 2479-2485.
12. Wessendorf S, Barth TF, Viardot A, et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia. 2007;21:2463-2469.
13. Oschlies I, Burkhardt B, Salaverria I, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96:262-268.
14. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268-3277.
15. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123:2062-2065.
16. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812-1826.
17. Twa DD, Mottok A, Chan FC, et al. Recurrent genomic rearrangements in primary testicular lymphoma. J Pathol. 2015. [Epub ahead of print].
18. Silacci P, Mottet A, Steimle V, et al. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med. 1994;180:1329-1336.
19. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377-381.
20. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118:2659-2669.
21. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
22. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-2323.
23. Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38:1715-1723.
24. Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997;15:1646-1653.
25. Saarinen S, Kaasinen E, Karjalainen-Lindsberg ML, et al. Primary mediastinal large B-cell lymphoma segregating in a family: exome sequencing identifies MLL as a candidate predisposition gene. Blood. 2013;121:3428-3430.
26. Okamura JM, Barr RJ. Cutaneous lymphoepithelial neoplasms. Adv Dermatol. 1997;12:277-294. discussion 295.
27. Hiraumi H, Tabuchi K, Kitajiri S. Dermal thymus: case report and review of the literature. Am J Otolaryngol. 2001;22:294-296.
28. Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121:2715-2724.
29. Maes B, Anastasopoulou A, Kluin-Nelemans JC, et al. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features. Ann Oncol. 2001;12:853-858.
30. Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18:590-605.
31. Eberle FC, Salaverria I, Steidl C, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011;24:1586-1597.